PE20030120A1 - Sal amina de un antagonista de receptor de integrin - Google Patents
Sal amina de un antagonista de receptor de integrinInfo
- Publication number
- PE20030120A1 PE20030120A1 PE2002000515A PE2002000515A PE20030120A1 PE 20030120 A1 PE20030120 A1 PE 20030120A1 PE 2002000515 A PE2002000515 A PE 2002000515A PE 2002000515 A PE2002000515 A PE 2002000515A PE 20030120 A1 PE20030120 A1 PE 20030120A1
- Authority
- PE
- Peru
- Prior art keywords
- salt
- refers
- hydroximethyl
- naphthyridin
- aminomethane
- Prior art date
Links
- -1 AMINE SALT Chemical class 0.000 title 1
- 102000006495 integrins Human genes 0.000 title 1
- 108010044426 integrins Proteins 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 abstract 3
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- LFQSCWFLJHTTHZ-HQMMCQRPSA-N Ethanol-14C Chemical compound C[14CH2]O LFQSCWFLJHTTHZ-HQMMCQRPSA-N 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 239000007983 Tris buffer Substances 0.000 abstract 1
- 206010057469 Vascular stenosis Diseases 0.000 abstract 1
- 238000002441 X-ray diffraction Methods 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 150000001450 anions Chemical class 0.000 abstract 1
- 150000001768 cations Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000002329 infrared spectrum Methods 0.000 abstract 1
- 150000002500 ions Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A UNA SAL AMINA DEL ACIDO 3-(PIRIMIDIN-5-IL)-9-(5,6,7,8-TETRAHIDRO-[1,8]-NAFTIRIDIN-2-IL)-NONANOICO O UN SOLVATO FARMACEUTICAMENTE ACEPTABLE CON INCLUSION DE HIDRATO DE FORMULA I QUE SE CARACTERIZA POR SU PATRON DE DIFRACCION DE RAYOS X QUE EXHIBE PICOS DE DIFRACCION CORRESPONDIENTE A ESPACIAMIENTOS d QUE VARIAN ENTRE 16,38A° Y 3,23A°, CURVA CALORIMETRICA DE EXPLORACION DIFERENCIAL, ESPECTRO DE RESONANCIA MAGNETICA NUCLEAR DE AMGPC EN ESTADO SOLIDO CARBONO 13 QUE MUESTRA SENALES ENTRE 179,0 Y 20,4, ESPECTRO INFRARROJO CON TF QUE MUESTRA BANDAS DE ABSORCION SIGNIFICATIVA ENTRE 3347 Y 659 cm(-1). TAMBIEN SE REFIERE A UNA SAL QUE COMPRENDE IONES DEL ANION ACIDO 3-(PIRIMIDIN-5-IL)-9-(5,6,7,8,-TETRAHIDRO-[1,8]-NAFTIRIDIN-2-IL)-NONANOICO Y EL CATION PROTONADO TRIS(HIDROXIMETIL)AMINOMETANO.TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION DE LA SAL QUE COMPRENDE PONER EN CONTACTO UN EQUIVALENTE MOLAR DEL COMPUESTO EN UN DISOLVENTE ORGANICO (METANOL, ETANOL, ENTRE OTROS) CON UN EQUIVALENTE MOLAR DE TRIS(HIDROXIMETIL)AMINOMETANO A UNA TEMPERATURA ENTRE LOS LIMITES DE 0°C A 100°C. LA SAL PUEDE SER UTL PARA EL TRATAMIENTO DE OSTEOPOROSIS, ENFERMEDAD O AFECCION CAUSADA POR UN EXCESO DE ANGIOGENESIS, DEGENERACION DE MACULA, RECURRENCIA DE ESTENOSIS VASCULAR, RETINOPATIA DIABETICA, ATEROSCLEROSIS, ARTRITIS INFLAMATORIA, CANCER, CRECIMIENTO TUMORAL METASTASICO
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29934401P | 2001-06-19 | 2001-06-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20030120A1 true PE20030120A1 (es) | 2003-02-12 |
Family
ID=23154380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002000515A PE20030120A1 (es) | 2001-06-19 | 2002-06-14 | Sal amina de un antagonista de receptor de integrin |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US6750220B2 (es) |
| DO (1) | DOP2002000420A (es) |
| PE (1) | PE20030120A1 (es) |
| WO (1) | WO2002102374A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2319596B1 (es) | 2006-12-22 | 2010-02-08 | Laboratorios Almirall S.A. | Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico. |
| UY31272A1 (es) | 2007-08-10 | 2009-01-30 | Almirall Lab | Nuevos derivados de ácido azabifenilaminobenzoico |
| EP2135610A1 (en) * | 2008-06-20 | 2009-12-23 | Laboratorios Almirall, S.A. | Combination comprising DHODH inhibitors and methotrexate |
| EP2239256A1 (en) | 2009-03-13 | 2010-10-13 | Almirall, S.A. | Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor |
| EP2230232A1 (en) * | 2009-03-13 | 2010-09-22 | Almirall, S.A. | Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors |
| EP2314577A1 (en) | 2009-10-16 | 2011-04-27 | Almirall, S.A. | Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid |
| SI3050878T1 (sl) | 2013-09-24 | 2022-01-31 | Fujifilm Corporation | Nova dušik-vsebujoča spojina ali njena sol ali kovinski kompleks le-te |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0100397A3 (en) * | 1997-12-17 | 2002-10-28 | Merck & Co Inc | Tetrahydro- or octahydrobenzonaphtyridin and quinolin derivatives, pharmaceutical compositions thereof and process for their preparation |
| US6048861A (en) | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
| US6444680B1 (en) * | 2000-11-30 | 2002-09-03 | Merck & Co., Inc. | Amine salts of an integrin receptor antagonist |
-
2002
- 2002-06-14 WO PCT/US2002/018906 patent/WO2002102374A1/en not_active Ceased
- 2002-06-14 PE PE2002000515A patent/PE20030120A1/es not_active Application Discontinuation
- 2002-06-18 US US10/174,016 patent/US6750220B2/en not_active Expired - Fee Related
- 2002-06-19 DO DO2002000420A patent/DOP2002000420A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002102374A1 (en) | 2002-12-27 |
| US20030004171A1 (en) | 2003-01-02 |
| US6750220B2 (en) | 2004-06-15 |
| DOP2002000420A (es) | 2002-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2751110B1 (en) | Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative and autoimmune diseases | |
| EP2789622B1 (en) | Pyrrolobenzodiazepines used to treat proliferative diseases | |
| EP2751120B1 (en) | Pyrrolobenzodiazepines as unsymmetrical dimeric pbd compounds for inclusion in targeted conjugates | |
| EP2906249B1 (en) | Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation | |
| EP1879901B1 (en) | Pyrrolobenzodiazepines | |
| EP2751111B1 (en) | Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative or autoimmune diseases | |
| CA2850375C (en) | Pyrrolobenzodiazepines and targeted conjugates | |
| AU2009305190B2 (en) | Unsymmetrical pyrrolobenzodiazepine-dimers for treatment of proliferative diseases | |
| AU2013255613A1 (en) | Pyrrolobenzodiazepines | |
| Ko et al. | Synthesis and in vitro photodynamic activities of water-soluble fluorinated tetrapyridylporphyrins as tumor photosensitizers | |
| El-Gamal et al. | Synthesis, in vitro antiproliferative activity, and in silico studies of fused tricyclic coumarin sulfonate derivatives | |
| Bourre et al. | Synthesis, and in vitro and in vivo evaluation of a diphenylchlorin sensitizer for photodynamic therapy | |
| HN1997000046A (es) | Derivados de indazol sustituidos y compuestos relacionados | |
| PE20030120A1 (es) | Sal amina de un antagonista de receptor de integrin | |
| CN108697713B (zh) | 用于制备三环pi3k抑制剂化合物的方法及用其治疗癌症的方法 | |
| Li et al. | Identification and enrichment of a UV-induced degradant of Anagrelide drug substance | |
| Kuzmina et al. | The Development of meso-Methyl-BODIPY Conjugates with Boc-seco-CBI and Cabozantinib: The Practical Challenges of Red-Light-Activated Prodrugs for Anticancer PDT | |
| CN118724922A (zh) | 唑啉铵芳醚类cyp1a1共价抑制剂及其制备方法和用途 | |
| Yin et al. | Unexpected formation of N-methylfulleropyrrolidines by the reaction of fullerene and gossypol and their bioactivity | |
| Schmidt | Investigations into the mechanism of the photodechlorination of pentachlorobenzene. | |
| HK1195073A (en) | Pyrrolobenzodiazepines as unsymmetrical dimeric pbd compounds for inclusion in targeted conjugates | |
| HK1256557A1 (en) | Pyrrolobenzodiazepines and targeted conjugates | |
| HK1195070A (en) | Asymmetrical bis-(5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative and autoimmune diseases | |
| HK1195070B (en) | Asymmetrical bis-(5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative and autoimmune diseases | |
| HK1213488B (en) | Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |